NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC

Barclays PLC increased its holdings in NewAmsterdam Pharma (NASDAQ:NAMS) by 1,813.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,596 shares of the company’s stock after purchasing an additional 7,199 shares during the quarter. Barclays PLC’s holdings in NewAmsterdam Pharma were worth $126,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Quarry LP raised its holdings in NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the period. Bellevue Group AG purchased a new stake in NewAmsterdam Pharma during the 3rd quarter worth approximately $128,000. Sei Investments Co. increased its stake in NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after buying an additional 8,087 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in NewAmsterdam Pharma by 3.7% during the 3rd quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company’s stock worth $4,237,000 after buying an additional 9,160 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in NewAmsterdam Pharma by 11.0% during the 3rd quarter. Wellington Management Group LLP now owns 92,223 shares of the company’s stock worth $1,531,000 after buying an additional 9,162 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Down 1.9 %

Shares of NewAmsterdam Pharma stock opened at $25.55 on Thursday. NewAmsterdam Pharma has a fifty-two week low of $12.04 and a fifty-two week high of $27.29. The stock has a 50 day moving average of $23.10 and a 200 day moving average of $19.60.

Insider Buying and Selling

In related news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the transaction, the insider now directly owns 11,778,760 shares in the company, valued at approximately $295,411,300.80. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 446,730 shares of company stock worth $11,438,695. Company insiders own 19.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on NAMS shares. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Scotiabank upped their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Piper Sandler restated an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, HC Wainwright assumed coverage on NewAmsterdam Pharma in a research report on Monday, December 30th. They issued a “buy” rating and a $48.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Buy” and an average price target of $38.17.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.